Brief: Ibio Inc Enters Exclusive License Agreement With AstralBio
22/04/2025 22:58
April 22 (Reuters) - iBio Inc IBIO.O: IBIO INC - ENTERS EXCLUSIVE LICENSE AGREEMENT WITH ASTRALBIO IBIO - LICENSING AGREEMENT WITH ASTRALBIO FOR PRECLINICAL FIRST-IN-CLASS ANTIBODY TARGETING ACTIVIN E IBIO INC - CO TO PAY $750,000 UPFRONT LICENSE FEE TO ASTRALBIO Source text: [ID:n0001420720-25-000020] Further company coverage: IBIO.O ((Reuters.Briefs@thomsonreuters.com))
Recent news on iBio
See all newsBrief: iBio - IBIO-610 Plus Semaglutide Preserves Lean Mass In Eight-Week Obese NHP Study
Brief: Ibio Reports Fiscal Year 2026 Financial Results And Provides Corporate Update
Brief: Ibio Reports Q3 Fiscal Year 2026 Financial Results And Provides Corporate Update
U.S. STOCKS ON THE MOVE-Meta, Legence, Chegg
U.S. STOCKS ON THE MOVE-Hims & Hers, Chewy, Longeveron